Hillel Tobias, MD, FACS: "What is the impact of hepatitis B in the US?"

Dr. Hillel Tobias was a keynote speaker at the B Informed Educational Forum Program held in New York on September 23, 2004. He is the Professor of Medicine at the New York University School of Medicine and Medical Director of the Liver Transplant Service at the New York University Medical Center. In addition, he is Chief Executive Officer and Medical Director of the Mary Lea Johnson Richards Research Institute, Inc.

His research interests are primarily devoted to the treatment of hepatitis, a subject on which he has authored or coauthored numerous articles. He is a Fellow of the American College of Physicians and a member of the Medical Advisory Board of the American Liver Foundation. He is coauthor of a recent publication in Clinical Gastroenterology and Hepatology entitled “A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States.” Dr. Tobias is also a director of the “Asian American Hepatitis B Project” a major program for the study and treatment of hepatitis B in the Asian communities of New York City, which is funded by a $4.5 million dollar grant from the New York City Council.

Dr. Tobias earned his MD at Washington University School of Medicine in St. Louis, Missouri and his Ph.D. in liver physiology at the University of London, England. After graduation from medical school, he completed his internship and medical residency at the New York University service of Bellevue Hospital. His postgraduate fellowships were served at the Royal Free Hospital, London, and the Mount Sinai Hospital in New York.